Investigating causes of heterogeneity in systematic reviews
- 21 May 2002
- journal article
- review article
- Published by Wiley in Statistics in Medicine
- Vol. 21 (11) , 1503-1511
- https://doi.org/10.1002/sim.1183
Abstract
What causes heterogeneity in systematic reviews of controlled trials? First, it may be an artefact of the summary measures used, of study design features such as duration of follow‐up or the reliability of outcome measures. Second, it may be due to real variation in the treatment effect and hence provides the opportunity to identify factors that may modify the impact of treatment. These factors may include features of the population such as: severity of illness, age and gender; intervention factors such as dose, timing or duration of treatment; and comparator factors such as the control group treatment or the co‐interventions in both groups. The ideal way to study causes of true variation is within rather than between studies. In most situations however, we will have to make do with a study level investigation and hence need to be careful about adjusting for potential confounding by artefactual factors such as study design features. Such investigation of artefactual and true causes of heterogeneity form essential steps in moving from a combined effect estimate to application to particular populations and individuals. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 19 references indexed in Scilit:
- Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomesStatistics in Medicine, 2002
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Antibiotics for acute otitis media in childrenPublished by Wiley ,2000
- The relation between treatment benefit and underlying risk in meta-analysisBMJ, 1996
- An evidence based approach to individualising treatmentBMJ, 1995
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsPublished by Elsevier ,1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological contextPublished by Elsevier ,1990
- Coronary arteriography 1984–1987: A report of the registry of the society for cardiac angiography and interventions. II. An analysis of 218 deaths related to coronary arteriographyCatheterization and Cardiovascular Diagnosis, 1989